We can also develop drugs for the METTL16_ YTHDF3_ SLC5A3 pathway, such as agents designed to regulate METTL16 to reduce ROS and change the expression of IGF2BP3 to improve haemoglobin, which will provide a new direction for the treatment of HbH disease. The gene discussed is IGF2BP3; the disease is hemoglobin H disease.